QRX003 lotion (4%) is being evaluated in two late-stage whole body pivotal clinical trials for Netherton Syndrome. Enrollment in both pivotal studies is expected to be completed in Q1 2026, top-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback